An Open-Label, Pilot Study to Evaluate the Efficacy of Narrowband Ultraviolet-B Phototherapy Three Times Weekly for Twelve Weeks in Moderate-to-Severe Psoriasis Patients

Description

A single center study of 30 patient receiving Narrowband UVB phototherapy three times weekly for 12 weeks. Patients will be evaluated through week 36 to evaluate maintenance of response.

Study Start Date

November, 07 2017

Estimated Completion Date

January 2019

Interventions

  • Device: Narrowband UVB phototherapy

Study ID

Psoriasis Treatment Center of Central New Jersey -- PTC02

Status

Unknown

Trial ID

NCT03392337

Study Type

Interventional

Trial Phase

N/A

Enrollment Quota

30

Sponsor

Psoriasis Treatment Center of Central New Jersey

Inclusion Criteria

    1. Male or female adults ? 18 years of age. 2. Diagnosis of chronic plaque-type psoriasis for at least 6 months 3. Moderate to Severe plaque psoriasis as defined by BSA ?10 PASI ?12 IGA ?3 4. Able to give written informed consent prior to performance of any study related procedures 5. Subject is able to attend Narrowband UVB phototherapy sessions three times a week and all other protocol specified visits 6. Subject must be in general good health (except for psoriasis) as judged by the Investigator, based on medical history, physical examination.

Exclusion Criteria

    1. Forms of psoriasis other than chronic plaque-type (e.g., pustular, erythrodermic, and/or guttate psoriasis) or drug induced psoriasis 2. History of photosensitivity 3. Subject has used ustekinumab and/or anti-IL-17 biologic therapy within 24 weeks or other experimental or commercially available biologic immune modulator(s) within 12 weeks prior to the first IP dose. 4. Use of any investigational drug within 4 weeks prior to randomization, or within 5 pharmacokinetic/pharmacodynamic half lives, if known (whichever is longer). 5. Use of oral systemic medications for the treatment of psoriasis within 4 weeks (includes, but not limited to, oral corticosteroids, methotrexate, acitretin, apremilast and cyclosporine). 6. Patient used topical therapies to treat within 2 weeks of the Baseline Visit (includes, but not limited to, topical corticosteroids, vitamin D analogs, or retinoids). 7. Initiated within 3 months, planned initiation of, or changes to, concomitant medications that could affect psoriasis vulgaris (e.g. beta blockers, antimalarial drugs, lithium, ACE inhibitors ) during the trial 8. Active infections requiring antibiotics in the 2 weeks prior to Baseline 9. Patient received UVB phototherapy within 4 weeks of Baseline. 10. Patient received PUVA phototherapy within 4 weeks of Baseline.

Gender

All

Ages

18 Years and older

Accepts Healthy Volunteers

No

Study Locations and Contact Information (1)

Study Location Distance Name Phone Email
Elise Nelson - East Windsor, New Jersey 94.1 miles Jerry Bagel 609-443-4500 dreamacres1@aol.com

ClinicalTrialsLocator.com provides clinical trial listings in an easy to view format. All clinical trial information is pulled directly from ClinicalTrials.gov. This website does not guarantee acceptance into any clinical trial, and is not responsible for adverse events that may be incurred from a clinical trial.